← Azimuth Daily
Capturing data…
Capturing data…
THU, 22 OCT · 89 ITEMS
STAT News, Reuters · Science & Medicine
The US FDA has approved (brand name Hibsago), a first-in-class drug developed by GSK in partnership with Ionis Pharmaceuticals, for the treatment of . Unlike standard antivirals that only suppress the virus, this drug targets the hepatitis B virus's genetic instructions, aiming for a '' that could allow some patients to stop long-term therapy. The approval is based on clinical trial data showing the drug can reduce viral levels enough to maintain undetectable virus after treatment stops, when used in combination with existing antivirals.
The claim is solid and directly supported by the FDA's own press release, GSK's corporate announcement, and multiple major news outlets (STAT, Reuters). All reporting closely paraphrases or quotes from these primary sources, and the FDA approval is an unambiguous regulatory action, so there is no room for misinterpretation.
Genuinely new: the FDA approval was announced on October 20–21, 2026, and coverage appeared within hours.
We covered an earlier milestone for this drug on August 25, 2026, when GSK announced regulatory wins for its chronic hepatitis B drug and a cancer therapy, hinting at the impending FDA decision.